NCT04871191View on ClinicalTrials.gov

Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

January 31, 2029

Conditions
Granulomatosis with PolyangiitisAnti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
DRUG

Rituximab

375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.

DRUG

Tocilizumab

Subcutaneous injection of 162 mg per week

DRUG

Tofacitinib

\- Tofacitinib, administered orally at a dose of 5 mg twice a day. Tofacitinib will start at week 0. Treatment will be continued until week 52

Trial Locations (1)

75020

Hôpital de la Croix Saint Simon, Paris

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER